| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/19/2013 | US20130243730 Rna interference for the treatment of heart failure |
| 09/19/2013 | US20130243727 Triazoles as inhibitors of fatty acid synthase |
| 09/19/2013 | US20130243726 Methods for treating hcv |
| 09/19/2013 | US20130243725 2'-substituted carba-nucleoside analogs for antiviral treatment |
| 09/19/2013 | US20130243720 Iron(II)-Containing A Treatments for Hyperphosphatemia |
| 09/19/2013 | US20130243707 Topical compositions |
| 09/19/2013 | US20130243705 Method for preventing or treating skin tumor |
| 09/19/2013 | US20130243698 Radical polarizing agents for dynamic nuclear polarization |
| 09/19/2013 | US20130243695 Chemoembolisation |
| 09/18/2013 | EP2639234A1 Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same |
| 09/18/2013 | EP2639230A1 Prolinamide derivative as thrombin inhibitor, preparation method and application thereof |
| 09/18/2013 | EP2639229A2 Thiazole Derivative and use thereof as VAP-1 Inhibitor |
| 09/18/2013 | EP2639227A1 A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents |
| 09/18/2013 | EP2639226A1 Anti-infective pyrimidines and uses thereof |
| 09/18/2013 | EP2639220A1 Indole derivatives and their use as antibiotics |
| 09/18/2013 | EP2639215A1 Salts of kukoamine b, preparation method and use thereof |
| 09/18/2013 | EP2638917A1 Method of fixing and expressing physiologically active substance |
| 09/18/2013 | EP2638913A1 Method for producing bioactive agent, bioactive agent produced thereby, cosmetic, freshness-maintaining agent, growth promotion agent, soil conditioning agent, and pharmaceutical stock solution |
| 09/18/2013 | EP2638912A1 Compositions containing antisense oligonucleotide to micro rna |
| 09/18/2013 | EP2638911A1 Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
| 09/18/2013 | EP2638910A2 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
| 09/18/2013 | EP2638909A1 Process for preparing sterile Brinzolamide |
| 09/18/2013 | EP2638908A1 Paralytic Shellfish Poison |
| 09/18/2013 | EP2638907A2 Combinations of an anti-HER2 antibody-drug conjugate and lapatinib |
| 09/18/2013 | EP2638906A1 Stabilized adhesive preparation containing donepezil |
| 09/18/2013 | EP2638905A2 Biofilm treatment |
| 09/18/2013 | EP2638904A1 Method for preventing or reducing postoperative adhesions |
| 09/18/2013 | EP2638903A1 Suppressor for increase in blood glucose level |
| 09/18/2013 | EP2638902A1 Antimalarial drug comprising alaremycin or derivative thereof as active ingredient |
| 09/18/2013 | EP2638901A1 Agent for inducing endogenous interferon |
| 09/18/2013 | EP2638900A1 Drug for treating liver lesions caused by the action of chemical or biological agents |
| 09/18/2013 | EP2638898A1 Metformin and Pioglitazone Formulation with Different Release Profiles |
| 09/18/2013 | EP2638897A1 Method for Manufacturing medicinal Compounds containing Dabigatran |
| 09/18/2013 | EP2638894A1 Pharmaceutical composition containing phospholipid |
| 09/18/2013 | EP2638812A1 Method for stimulating the intestinal flora |
| 09/18/2013 | EP2638076A2 Novel photoinitiators |
| 09/18/2013 | EP2638056A1 Use of 2',5'-oligoadenylate derivative compounds |
| 09/18/2013 | EP2638054A1 Uracyl spirooxetane nucleoside phosphoramidates |
| 09/18/2013 | EP2638053A1 Uracyl spirooxetane nucleoside phosphoramidates |
| 09/18/2013 | EP2638052A1 Selective glycosidase inhibitors and uses thereof |
| 09/18/2013 | EP2638047A1 Substituted 4-beta-acrylamidopodophyllotoxin congeners as antitumour antibiotics and the process for preparation thereof |
| 09/18/2013 | EP2638046A2 Spiro-oxindole mdm2 antagonists |
| 09/18/2013 | EP2638043A1 Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines |
| 09/18/2013 | EP2638042A1 Piperidinone carboxamide azaindane cgrp receptor antagonists |
| 09/18/2013 | EP2638041A1 Substituted azaindazole compounds |
| 09/18/2013 | EP2638039A1 Crystalline solifenacin succinate |
| 09/18/2013 | EP2638038A1 Method of treatment for mental disorders |
| 09/18/2013 | EP2638036A1 Compound for increasing kinase active and application thereof |
| 09/18/2013 | EP2638035A1 Triazole derivatives as ligands for gaba receptors |
| 09/18/2013 | EP2638033A1 Compounds useful for inhibiting chk1 |
| 09/18/2013 | EP2638032A1 Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses |
| 09/18/2013 | EP2638031A1 Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| 09/18/2013 | EP2638030A1 Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| 09/18/2013 | EP2638029A1 Triazole derivatives and their use for neurological disorders |
| 09/18/2013 | EP2638026A2 Chromene derivatives and their analoga as wnt pathway antagonists |
| 09/18/2013 | EP2638025A2 Chromene derivatives and their analoga as wnt pathway antagonists |
| 09/18/2013 | EP2638023A1 Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| 09/18/2013 | EP2638021A2 Metalloenzyme inhibitor compounds |
| 09/18/2013 | EP2638018A1 Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| 09/18/2013 | EP2638017A1 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| 09/18/2013 | EP2638015A1 Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands |
| 09/18/2013 | EP2638012A1 Pyridyl ureas as mineralocorticoid receptor antagonists |
| 09/18/2013 | EP2638009A2 Fluorinated hdac inhibitors and uses thereof |
| 09/18/2013 | EP2638008A1 Lactam derivatives useful as orexin receptor antagonists |
| 09/18/2013 | EP2638006A1 Hydroxamic acid derivatives and their use in the treatment of bacterial infections |
| 09/18/2013 | EP2638005A2 S-t-butyl protected cysteine di-peptide analogs and related compounds |
| 09/18/2013 | EP2637695A1 Olmesartan formulations |
| 09/18/2013 | EP2637673A1 Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
| 09/18/2013 | EP2637672A1 Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd). |
| 09/18/2013 | EP2637671A2 Cardiac glycoside analogs in combination with emodin for cancer therapy |
| 09/18/2013 | EP2637670A1 Prevention of adverse effects caused by cd3 specific binding domains |
| 09/18/2013 | EP2637669A2 Heterocyclic compounds and uses thereof |
| 09/18/2013 | EP2637668A1 Ibat inhibitors for the treatment of liver diseases |
| 09/18/2013 | EP2637667A1 Ibat inhibitors for treatment of metabolic disorders and related conditions |
| 09/18/2013 | EP2637666A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferative disorders |
| 09/18/2013 | EP2637665A1 Dexamethasone combination therapy |
| 09/18/2013 | EP2637664A2 Compositions and methods of treating pulmonary hypertension |
| 09/18/2013 | EP2637663A1 Combination therapy with an antitumor alkaloid |
| 09/18/2013 | EP2637662A1 Dosing regimen for sedation with cns 7056 (remimazolam) |
| 09/18/2013 | EP2637661A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/18/2013 | EP2637660A1 Fatty acid synthase inhibitors |
| 09/18/2013 | EP2637659A1 Sgc stimulators |
| 09/18/2013 | EP2637658A1 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 09/18/2013 | EP2637657A1 Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| 09/18/2013 | EP2637656A1 Piperidinone carboxamide indane cgrp receptor antagonists |
| 09/18/2013 | EP2637655A1 Pharmaceutical composition of taxoids |
| 09/18/2013 | EP2637654A1 Topical organic acid salt compositions suitable for treating infections |
| 09/18/2013 | EP2637653A1 Compositions comprising wnt inhibitors for treating cancer |
| 09/18/2013 | EP2637652A2 Osteoclast activity |
| 09/18/2013 | EP2637651A1 Composition for treating phonatory and olfactory apparatus disorders |
| 09/18/2013 | EP2637650A2 Methods to test allergic conditions |
| 09/18/2013 | EP2637649A2 Compounds and methods for treating pain |
| 09/18/2013 | EP2637648A1 Pharmaceutical composition, methods for treating and uses thereof |
| 09/18/2013 | EP2637646A1 A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| 09/18/2013 | EP2637645A2 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof |
| 09/18/2013 | EP2637644A1 Lisuride, terguride and derivatives thereof for use in the prophylaxis and/or treatment of fibrotic changes |
| 09/18/2013 | EP2637643A2 Pharmaceutical composition for treating hcv infections |
| 09/18/2013 | EP2637642A1 Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| 09/18/2013 | EP2637641A2 Metabolized conditioned growth medium and methods of use |
| 09/18/2013 | EP2637511A1 Methods of improving mental or physical health conditions in an individual |